ONCOMATRYX
Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.
ONCOMATRYX
Industry:
Biopharma Biotechnology Health Care
Founded:
2009-01-01
Address:
Derio, Pais Vasco, Spain
Country:
Spain
Website Url:
http://www.oncomatryx.com
Total Employee:
11+
Status:
Active
Contact:
+34 946 087 037
Total Funding:
19.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Google Universal Analytics Wordpress Plugins Sitelinks Search Box
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Employees Featured
Founder
Investors List
Gestion De Capital Riesgo Del Pais Vasco
Gestion De Capital Riesgo Del Pais Vasco investment in Venture Round - Oncomatryx
Official Site Inspections
http://www.oncomatryx.com
- Host name: llgm941.servidoresdns.net
- IP address: 217.76.142.247
- Location: Spain
- Latitude: 40.4172
- Longitude: -3.684
- Timezone: Europe/Madrid
More informations about "Oncomatryx"
Oncomatryx
Apr 19, 2022 Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat …See details»
Oncomatryx - Wikipedia
Oncomatryx Biopharma S. L. is a pharmaceutical biotechnology company that develops personalized treatments against invasive cancer as well as tests for its early detection. Established by Laureano Simón, PhD, Oncomatryx thus engages twofold in the fight against invasive kinds of cancer, such as pancreatic cancer or invasive breast cancer, all of which have high mortality rates. See details»
Oncomatryx - Crunchbase Company Profile & Funding
Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic …See details»
Oncomatryx Company Profile | Management and Employees List
Oncomatryx is focused on the development of personalized biological treatments, to fight against invasive tumors. The company is based in the Bizkaia Technology Park, in the Basque …See details»
Oncomatryx - Products, Competitors, Financials, Employees, …
Oncomatryx is a biopharmaceutical company that develops the tumor microenvironment within cancer treatment. Use the CB Insights Platform to explore Oncomatryx's full profile. ... May 6, …See details»
Oncomatryx Company Profile - Office Locations, Competitors
Oncomatryx Biopharma is a biopharmaceutical company focused on the tumor microenvironment. It develops drugs and diagnostic devices that target the tumor stroma. Its Antibody-Drug …See details»
Oncomatryx - Overview, News & Competitors | ZoomInfo.com
Oncomatryx carries out the development of Diagnostic devices and Antibody-Drug Conjugates and Immunotoxins against these novel targets, in collaboration with reference research …See details»
About us – Oncomatryx
After all of these years full of research and passion, at Oncomatryx we have established the critical role that Cancer Associated Fibroblasts play in tumor …See details»
Oncomatryx Biopharma SL - Drug pipelines, Patents, Clinical
May 8, 2025 Oncomatryx pioneering ADCs against immunosuppressive CAFs are developed in collaboration with prestigious universities, hospitals and research centers in USA and Europe. …See details»
ONCOMATRYX BIOPHARMA - VentureRadar
Oncomatryx is a biopharmaceutical company specializing in the development of proprietary Antibody-Drug Conjugates (ADCs) aimed at targeting Cancer-Associated Fibroblasts within …See details»
Oncomatryx closes its investmnet round with 15 million raised
Mar 18, 2022 Oncomatryx, a start-up member of the Basque Health Cluster, has started the year by raising 15 million euros to carry out phase I clinical trials.In addition to its existing …See details»
ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials
ZAMUDIO, Spain, January 27, 2025--ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund …See details»
Oncomatryx - Contacts, Employees, Board Members, Advisors
Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. AI Content may contain mistakes and is not legal, financial or investment advice.See details»
PRESS Releases - ONCOMATRYX
Jan 2, 2025 ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials …See details»
ONCOMATRYX raises €25 Million to foster OMTX705 Clinical Trials
January 29, 2025 January 15, 2025 by Oncomatryx ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised …See details»
ADC Platform – Oncomatryx
Oncomatryx has developed its own platform of Antibody-Drug Conjugates (ADCs) targeting the tumor microenvironment. This is a new generation of drugs to treat once incurable metastatic …See details»
Oncomatryx Secures €25M to Advance OMTX705 Clinical Trials
Jan 27, 2025 Oncomatryx, a biopharmaceutical company developing antibody-drug conjugates (ADCs), secured €25 million to advance clinical trials of OMTX705, a first-in-class ADC …See details»
TFS HealthScience Expands Collaboration with Oncomatryx for …
May 6, 2025 TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company …See details»
ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials
Jan 27, 2025 ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical …See details»
Clinical trials – Oncomatryx
What is an Oncology Clinical Trial? A clinical trial in oncology is a critical step in developing new cancer treatments. Its primary goal is to evaluate the effectiveness of newly developed drugs …See details»